Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vasopressin
- Development stage
- Approved
- Lead developer
- PH Health
- Modality
- Peptides
- Administration
- Intravenous, Intramuscular, Subcutaneous, Intranasal
01
Overview
Vasopressin is a peptide hormone used to increase blood pressure in patients with vasodilatory shock who are resistant to fluid and catecholamine therapy. It is also used to manage anti-diuretic hormone deficiency, such as in diabetes insipidus, by reducing urine flow through its action on renal V2 receptors. Additionally, vasopressin causes vasoconstriction via V1 receptors, which helps in increasing systemic vascular resistance and mean arterial blood pressure.
- Brand names
- VasostrictPitressin
- Other names
- antidiuretic hormone (ADH)arginine-vasopressin (AVP)
02
Targets
Oxytocin receptorAVPR1A (Arginine vasopressin receptor 1A)AVPR1B (Vasopressin V1b Receptor)AVPR2 (Arginine vasopressin V2 receptor)
Beyond the preview
Go deeper on vasopressin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vasopressin.